<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00080912</url>
  </required_header>
  <id_info>
    <org_study_id>SC20</org_study_id>
    <secondary_id>CAN-NCIC-SC20</secondary_id>
    <secondary_id>RTOG-0433</secondary_id>
    <secondary_id>TROG-03.08</secondary_id>
    <secondary_id>CDR0000357423</secondary_id>
    <nct_id>NCT00080912</nct_id>
    <nct_alias>NCT00797173</nct_alias>
  </id_info>
  <brief_title>Single-Fraction Compared With Multiple-Fraction Therapy in Treating Patients With Previously Irradiated Painful Bone Metastases</brief_title>
  <official_title>A Phase III International Randomized Trial Of Single Versus Multiple Fractions For Re-Irradiation Of Painful Bone Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Trans-Tasman Radiation Oncology Group (TROG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dutch Bone Metastasis Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet
      known whether single-fraction (single-dose) re-irradiation therapy is as effective as
      multiple-fraction (many small doses of radiation therapy) re-irradiation therapy in relieving
      bone pain caused by bone metastases.

      PURPOSE: This randomized phase III trial is studying single-dose radiation therapy to see if
      it works as well as multiple-dose radiation therapy in treating patients previously
      irradiated with painful bone metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare pain relief in patients undergoing single-fraction vs multiple-fraction
           re-irradiation of painful bone metastases at 2 months after treatment.

      Secondary

        -  Compare overall pain relief in patients treated with these regimens.

        -  Compare time to pain progression in patients treated with these regimens.

        -  Assess relationship between response to initial radiation and pain relief after
           re-irradiation in these patients.

        -  Compare changes in functional interference after re-irradiation using the Brief Pain
           Inventory in patients treated with these regimens.

        -  Compare quality of life of patients treated with these regimens (patients in Canada,
           France, the Netherlands, and patients registered through RTOG).

        -  Determine characteristics of non-responders (to both initial and re-irradiation) among
           patients treated with these regimens.

        -  Monitor the incidence of acute severe radiation-related side effects in patients treated
           with these regimens.

        -  Monitor the incidence of in-field pathological fractures and spinal cord compression in
           patients treated with these regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      response to initial radiotherapy (yes vs no), initial fractionation (single fraction vs
      multiple fraction), and participating center. Patients are randomized to 1 of 2 treatment
      arms.

        -  Arm I: Patients receive single-fraction radiotherapy (8Gy) on day 1.

        -  Arm II: Patients receive multiple-fraction radiotherapy (to a total of 20Gy) over 5 days
           or over 8 days if re-irradiation of the spine and/or whole pelvis is involved AND prior
           initial radiotherapy was given in multiple fractions.

      At least 4 weeks after the first re-treatment, patients in both arms may receive a second
      re-treatment at the discretion of the treating oncologist.

      Patients complete a Brief Pain Inventory questionnaire at baseline, on days 7 and 14, monthly
      during months 1-6, and at months 9 and 12. Acute Toxicities are assessed on days 7 and 14.
      Quality of Life is assessed at baseline and then monthly during months 1-6 for patients from
      participating groups.

      Patients are followed for up to 1 year.

      Peer Reviewed and Funded or Endorsed by Cancer Research UK

      PROJECTED ACCRUAL: A total of 850 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Relief Measured by the Brief Pain Inventory at 2 Months After Treatment</measure>
    <time_frame>2 months</time_frame>
    <description>The primary endpoint of this study is Overall Response Rate (complete response and partial response) at two months after the first fraction of re-irradiation; patients with a third radiation treatment (the second re-irradiation) before month two will not have response attributed to the study treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">850</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive single-fraction radiotherapy (8 Gy) on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive multiple-fraction radiotherapy (to a total of 20 Gy) over 5 days or over 8 days if re-irradiation of the spine and/or whole pelvis is involved AND prior initial radiotherapy was given in multiple fractions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Given in a single fraction or multiple fractions</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed malignancy

               -  Diagnosis by needle biopsy, bone marrow biopsy, cytology, or surgical biopsy or
                  resection

          -  Bone metastases at clinically painful areas confirmed by any of the following:

               -  Plain radiographs

               -  Radionuclide bone scans

               -  CT scans

               -  Magnetic resonance imaging

          -  Worst pain score of ≥ 2/10 using the baseline Brief Pain Inventory

          -  Pain arising from previously irradiated metastases and not from progressive disease in
             adjoining or remote areas

          -  Initial radiotherapy field is reproducible for re-irradiation

               -  Current treatment field for palliative radiotherapy must be the same size or
                  smaller than the initial treatment field

          -  No clinical or radiological evidence of pathological fractures in the target site
             extremities.

          -  No radiological evidence of high-risk lesions for pathological fractures in the
             extremities (lytic lesions &gt; 3cm or &gt; 50% cortical erosion of bone diameter) if target
             site AND patient is a candidate for surgical intervention.

          -  No clinical or radiological evidence of spinal cord compression at target site.

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Karnofsky 50-100%

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective barrier contraception

          -  Able and willing to complete quality of life questionnaire in English, French, Dutch,
             or Spanish (if randomized by Canadian, Dutch, French or RTOG centre)

          -  Must be accessible for treatment follow-up

          -  Informed consent

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  See Disease Characteristics

          -  No more than 1 prior course of radiotherapy to the target site

          -  No prior radiotherapy dose ≥ 24 Gy in 6 fractions, 27 Gy in 8 fractions, or 30 Gy in
             10 fractions to the spine or any part of the pelvis encompassing small or large bowel
             and/or the rectum, if these sites are being treated on study

               -  Initial doses of 24 Gy in 6 fractions, 27 Gy in 8 fractions or 30 Gy in 10
                  fractions to the acetabulum or hip and proximal femur allowed as long as the
                  medial field border of the initial treatment did not cross midline

          -  No prior radiotherapy dose &gt; 30Gy in 10 fractions to the ribs or extremities if these
             sites are being treated on study

          -  More than 30 days since prior strontium chloride Sr 89

          -  More than 30 days since prior half-body radiotherapy, including the current
             re-irradiation field

          -  At least 4 weeks since initial radiotherapy

        Surgery

          -  No prior palliative surgery in treatment area

          -  No concurrent surgical intervention on treatment area

        Other

          -  No prior participation on this protocol

          -  No plan to make an immediate change in analgesic regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward LW Chow, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Toronto Sunnybrook Regional Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William F. Hartsell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Advocate Good Samaratin Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Roos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Adelaide Hospital Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yvette von der Linden</last_name>
    <role>Study Chair</role>
    <affiliation>Radiotherapeutic Institution Friesland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Hoskin</last_name>
    <role>Study Chair</role>
    <affiliation>Mount Vernon Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vitalite Health Network - Dr. Leon Richard</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand River Regional Cancer Centre</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Science Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Dept. Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Chow E, Hoskin PJ, Wu J, Roos D, van der Linden Y, Hartsell W, Vieth R, Wilson C, Pater J. A phase III international randomised trial comparing single with multiple fractions for re-irradiation of painful bone metastases: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) SC 20. Clin Oncol (R Coll Radiol). 2006 Mar;18(2):125-8. Review.</citation>
    <PMID>16523812</PMID>
  </reference>
  <reference>
    <citation>Chow E, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, Brundage MD, Nabid A, Tissing-Tan CJ, Oei B, Babington S, Demas WF, Wilson CF, Meyer RM, Chen BE, Wong RK. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol. 2014 Feb;15(2):164-71. doi: 10.1016/S1470-2045(13)70556-4. Epub 2013 Dec 23.</citation>
    <PMID>24369114</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2004</study_first_submitted>
  <study_first_submitted_qc>April 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2004</study_first_posted>
  <results_first_submitted>February 11, 2015</results_first_submitted>
  <results_first_submitted_qc>February 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2015</results_first_posted>
  <last_update_submitted>February 11, 2015</last_update_submitted>
  <last_update_submitted_qc>February 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone metastases</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single-fraction</title>
          <description>Patients receive single-fraction radiotherapy (8 Gy) on day 1.
radiation therapy: Given in a single fraction or multiple fractions</description>
        </group>
        <group group_id="P2">
          <title>Multiple-fraction</title>
          <description>Patients receive multiple-fraction radiotherapy (to a total of 20 Gy) over 5 days or over 8 days if re-irradiation of the spine and/or whole pelvis is involved AND prior initial radiotherapy was given in multiple fractions.
radiation therapy: Given in a single fraction or multiple fractions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="425"/>
                <participants group_id="P2" count="425"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="425"/>
                <participants group_id="P2" count="425"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single-fraction</title>
          <description>Patients receive single-fraction radiotherapy (8 Gy) on day 1.
radiation therapy: Given in a single fraction or multiple fractions</description>
        </group>
        <group group_id="B2">
          <title>Multiple-fraction</title>
          <description>Patients receive multiple-fraction radiotherapy (to a total of 20 Gy) over 5 days or over 8 days if re-irradiation of the spine and/or whole pelvis is involved AND prior initial radiotherapy was given in multiple fractions.
radiation therapy: Given in a single fraction or multiple fractions</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="424"/>
            <count group_id="B2" value="423"/>
            <count group_id="B3" value="847"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" lower_limit="18.4" upper_limit="94.5"/>
                    <measurement group_id="B2" value="65.3" lower_limit="32.0" upper_limit="93.0"/>
                    <measurement group_id="B3" value="65.1" lower_limit="18.4" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="256"/>
                    <measurement group_id="B3" value="499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Relief Measured by the Brief Pain Inventory at 2 Months After Treatment</title>
        <description>The primary endpoint of this study is Overall Response Rate (complete response and partial response) at two months after the first fraction of re-irradiation; patients with a third radiation treatment (the second re-irradiation) before month two will not have response attributed to the study treatment.</description>
        <time_frame>2 months</time_frame>
        <population>Intend to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>Single-fraction</title>
            <description>Patients receive single-fraction radiotherapy (8 Gy) on day 1.
radiation therapy: Given in a single fraction or multiple fractions</description>
          </group>
          <group group_id="O2">
            <title>Multiple-fraction</title>
            <description>Patients receive multiple-fraction radiotherapy (to a total of 20 Gy) over 5 days or over 8 days if re-irradiation of the spine and/or whole pelvis is involved AND prior initial radiotherapy was given in multiple fractions.
radiation therapy: Given in a single fraction or multiple fractions</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief Measured by the Brief Pain Inventory at 2 Months After Treatment</title>
          <description>The primary endpoint of this study is Overall Response Rate (complete response and partial response) at two months after the first fraction of re-irradiation; patients with a third radiation treatment (the second re-irradiation) before month two will not have response attributed to the study treatment.</description>
          <population>Intend to treat (ITT) population</population>
          <units>percentage of response</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="425"/>
                <count group_id="O2" value="425"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" lower_limit="24.0" upper_limit="32.0"/>
                    <measurement group_id="O2" value="32.0" lower_limit="27.0" upper_limit="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The original sample size was determined based on the non-inferiority. The original sample size is based on assumption of response rate on the multiple fraction arm is 70%, 260 patients were required in each treatment arm to have 80% power to exclude, with a one sided alpha of 0.05, a response rate of 60% or less in the single fraction radiation group (non-inferiority margin =10%). Given an inevaluability rate of 30%, 850 patients (325 for each treatment arm) were randomized to the study.</non_inferiority_desc>
            <p_value>0.03</p_value>
            <p_value_desc>p-value is for one-sided non-inferiority test</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>9.2</ci_upper_limit>
            <estimate_desc>The upper limit of one-sided 95% CI for the response rate difference was 9.2%, which was below the pre-specified 10% non-inferiority boundary</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8.2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Single-fraction</title>
          <description>Patients receive single-fraction radiotherapy (8 Gy) on day 1.
radiation therapy: Given in a single fraction or multiple fractions</description>
        </group>
        <group group_id="E2">
          <title>Multiple-fraction</title>
          <description>Patients receive multiple-fraction radiotherapy (to a total of 20 Gy) over 5 days or over 8 days if re-irradiation of the spine and/or whole pelvis is involved AND prior initial radiotherapy was given in multiple fractions.
radiation therapy: Given in a single fraction or multiple fractions</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="425"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Bingshu Chen</name_or_title>
      <organization>NCIC Clinical Trials Group</organization>
      <phone>613-533-6000 ext 77703</phone>
      <email>bechen@ctg.queensu.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

